Drug intelligence / Profile preview

Zhejiang Univ. RIPK1 compound 15

Development stage: Unknown
Lead developer: Zhejiang University

Overview

Zhejiang Univ. RIPK1 compound 15: sourced facts only. name: "Based on the pharmacophore-based virtual screening, compound 15, a tetrahydropyrrolo[3,4-c]pyrrole-1,3-dione derivative, was identified as a hit of RIPK1 inhibitor with an IC50 value of 6.42 μM." [PMID:42043293]; target: "Based on the pharmacophore-based virtual screening, compound 15, a tetrahydropyrrolo[3,4-c]pyrrole-1,3-dione derivative, was identified as a hit of RIPK1 inhibitor with an IC50 value of 6.42 μM." [PMID:42043293]; developer: "College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China." [PMID:42043293]

Targets

RIPK1 (Receptor-interacting serine/threonine-protein kinase 1)

Beyond the preview

Go deeper on Zhejiang Univ. RIPK1 compound 15.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhejiang Univ. RIPK1 compound 15.